Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives

On the occasion of the 17th International Conference of Genomics (ICG-17) jointly organized by BGI Genomics in Riga, Dr. Ivana Morić, a research professor from the Institute of Molecular Genetic and Genetic Engineering (IMGGE) at the University of Belgrade shared first-hand insights about the implementation of high-throughput sequencing in Serbia and its exciting future.

Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives

Serbian scientists undergoing WES and WGS training. Image Credit: BGI Genomics

Dr. Morić began by introducing IMGGE’s research interest which is built around two main pillars. The first pillar is related to human health improvements, such as rare diseases, complex disorders, pharmacogenomics, bioinformatics, host-microbiota interactions, and novel antimicrobial and anti-virulence agents’ development. The second pillar is dedicated to green molecular biotechnologies, such as bio-catalysis and green processes, and the development of biodegradable materials.

Racing against the pandemic 

Upon the COVID-19 pandemic being declared in early 2020, the IMGGE team immediately thought about offering its expertise in molecular diagnostic methods. Collaboration between IMGGE and BGI began with the building of two permanent Huoyan laboratories. 

Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives

Serbian Prime Minister Ana Brnabic speaks at the opening of the Center in Dec 2021. Image Credit: BGI Genomics

Only 40 days after the pandemic was declared, the first laboratory was set up at the premises of the University Clinical Center of Serbia. This laboratory in Belgrade became one of two National Laboratories for Molecular Diagnostics of Infectious Agents. The second National Laboratory was strategically placed in the southern Serbian city of Nis to cover that area and was ready by July 2020. 

Seizing the momentum for public health 

Deciding to build upon this momentum to further contribute to the health of the nation, IMGGE collaborated with BGI again to build the Serbian Center for Genome Sequencing and Bioinformatics. And that happened very quickly as well. The construction started in September 2021 and three months later, the opening ceremony was held.

During these three months, the staff attended ten different online training sessions. Subsequently, the staff progressively underwent extensive onsite training related to COVID-19, whole exome sequencing (WES), whole genome sequencing (WGS), and noninvasive prenatal testing (NIPT). 

This training provided a good foundation for the Center’s research, such as the Omicron strain that hospitalized people in Serbia in April 2022.

We performed the first-ever WES and WGS sequencing in Serbia. NIFTY test onsite training was also performed in April 2022. Up till then, we had to send samples outside Serbia for testing. But hopefully from now on, these tests will be performed in Serbia.

Dr. Morić

More independent, yet more connected

The Center’s new facilities enabled it to apply for European-scale projects, such as Horizon Europe Program, and the first one to receive the funding was ‟Pharmacogenomics Hub in a Strengthened IMGGE - PharmGenHUB”, where 250 whole genomes will be sequenced. It also means that the Center can pour more targeted efforts into services like noninvasive prenatal testing. The Center also plans to offer NIFTY Pro testing to the Serbian population.

Dr. Morić noted Serbia’s strategic location in the Balkans and if Serbia’s neighbors are interested, the Center can offer its NIFTY solutions to them since the transportation costs associated with these tests will be relatively lower. 

The path toward globally integrated research

The implementation of high-throughput sequencing is aligned with the transformation the IMGGE is undertaking. The Government of the Republic of Serbia plans to build the BIO4 campus in Belgrade, a 20-hectare facility focusing on four key areas: Biomedicine, Biotechnology, Bioinformatics and Biodiversity. This campus targets to be up and running by 2024. 

Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives

Artist's impression of the future BIO4 campus. Image Credit: BGI Genomics

The Serbian Government envisions the BIO4 campus as a place to reinforce and connect international research through global collaboration.

BGI will be present at the BIO4 campus and I sincerely invite other potential partners to contact us, to explore collaboration.

Dr. Ivana Morić

The Serbian implementation of high-throughput sequencing | BGI Gene Test

Video Credit: BGI Genomics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BGI Genomics. (2022, November 23). Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/20221114/Serbiae28099s-high-throughput-genetic-sequencing-implementation-7c-BGI-Perspectives.aspx.

  • MLA

    BGI Genomics. "Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives". News-Medical. 22 December 2024. <https://www.news-medical.net/news/20221114/Serbiae28099s-high-throughput-genetic-sequencing-implementation-7c-BGI-Perspectives.aspx>.

  • Chicago

    BGI Genomics. "Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives". News-Medical. https://www.news-medical.net/news/20221114/Serbiae28099s-high-throughput-genetic-sequencing-implementation-7c-BGI-Perspectives.aspx. (accessed December 22, 2024).

  • Harvard

    BGI Genomics. 2022. Serbia’s high-throughput genetic sequencing implementation | BGI Perspectives. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/20221114/Serbiae28099s-high-throughput-genetic-sequencing-implementation-7c-BGI-Perspectives.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The Applications of Non-Invasive Prenatal Testing (NIPT) - 10 Years of Experience